About Bilthoven Biologicals
Bilthoven Biologicals is a company based in Bilthoven (Netherlands) founded in 2012 was acquired by Serum Institute of India in July 2012.. Bilthoven Biologicals offers products and services including BCG Vaccine, Tetanus Vaccine, DTP Vaccine, and Poliomyelitis Vaccine (IPV). Bilthoven Biologicals operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, HOOKIPA Pharma, Vir Biotechnology and Biological E, among others.
- Headquarter Bilthoven, Netherlands
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$28.65 M (USD), Grant
Jun 30, 2023
-
Investors
Serum Institute of India
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Serum Institute of India
(Jul 03, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Bilthoven Biologicals
Bilthoven Biologicals offers a comprehensive portfolio of products and services, including BCG Vaccine, Tetanus Vaccine, DTP Vaccine, and Poliomyelitis Vaccine (IPV). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Protects against tuberculosis through immunization.
Prevents tetanus infections via injection.
Guards against diphtheria, tetanus, and pertussis.
Inactivated vaccine to prevent polio disease.
Unlock access to complete
Funding Insights of Bilthoven Biologicals
- Total Funding Total Funding
- Total Rounds 1
- Last Round Grant — $28.6M
-
First Round
First Round
(30 Jun 2023)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2023 | Amount | Grant - Bilthoven Biologicals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Bilthoven Biologicals
Bilthoven Biologicals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Serum Institute of India and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Bilthoven Biologicals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Bilthoven Biologicals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Bilthoven Biologicals Comparisons
Competitors of Bilthoven Biologicals
Bilthoven Biologicals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, HOOKIPA Pharma, Vir Biotechnology and Biological E, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Bilthoven Biologicals
Frequently Asked Questions about Bilthoven Biologicals
When was Bilthoven Biologicals founded?
Bilthoven Biologicals was founded in 2012 and raised its 1st funding round 11 years after it was founded.
Where is Bilthoven Biologicals located?
Bilthoven Biologicals is headquartered in Bilthoven, Netherlands. It is registered at Bilthoven, Utrecht, Netherlands.
Who is the current CEO of Bilthoven Biologicals?
Jan-Eric Zandbergen is the current CEO of Bilthoven Biologicals.
What does Bilthoven Biologicals do?
Bilthoven Biologicals, based in Bilthoven, Netherlands, was acquired by the Poonawalla Group in July 2012. Vaccines targeting infectious diseases, including polio and tetanus, are produced on a large scale by the company. Operations involve manufacturing over 20 million units each year, with distribution occurring in more than 25 countries within the biopharmaceutical sector.
Who are the top competitors of Bilthoven Biologicals?
Bilthoven Biologicals's top competitors include Vaxcyte, HOOKIPA Pharma and Serum Institute of India.
What products or services does Bilthoven Biologicals offer?
Bilthoven Biologicals offers BCG Vaccine, Tetanus Vaccine, DTP Vaccine, and Poliomyelitis Vaccine (IPV).
Who are Bilthoven Biologicals's investors?
Bilthoven Biologicals has 2 investors. Key investors include Serum Institute of India, and European Union.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.